Background. Spontaneous reports of herb induced liver injury (HILI) represent a major regulatory issue, and it is in the interest of pharmacovigilance to identify and quantify previously unrecognized adverse reactions and to confirm or refute false positive signals of safety concerns. In a total of 13 spontaneous cases, liver disease has initially been attributed to the use of Pelargonium sidoides (PS), a plant from the South African region. Water/ethanol extracts derived from its roots are available as registered herbal drugs for the treatment of upper respiratory tract infections including acute bronchitis. Objectives. The present study examines whether and to what extent treatment by PS was associated with the risk of liver injury in these spontaneous cases. Study design: Overall, 13 spontaneous cases with primarily suspected PS hepatotoxicity were included in the study. Their data were submitted to a thorough clinical evaluation that included the use of the original and updated scale of CIOMS (Council for International Organizations of Medical Sciences) to assess causality levels. These scales are liver specific, validated for liver toxicity, structured and quantitative. Results. None of the 13 spontaneous cases of liver disease generated a positive signal of safety concern, since causality for PS could not be established on the basis of the applied CIOMS scales in any of the assessed patients. Confounding variables included comedication with synthetic drugs, major comorbidities, low data quality, lack of appropriate consideration of differential diagnoses, and multiple alternative diagnoses. Among these were liver injury due to comedication, acute pancreatitis and cholangitis, acute cholecystitis, hepatic involvement following lung contusion, hepatitis in the course of virus and bacterial infections, ANA positive autoimmune hepatitis, and other preexisting liver diseases. In the course of the case assessments and under pharmacovigilance aspects, data and interpretation deficits became evident. Possible improvements include appropriate data quality of cases in spontaneous reports, case assessment by skilled specialists, use of a validated liver specific causality assessment method, and inclusion only of confirmed cases into the final regulatory case database. Conclusions. This study shows lack of hepatotoxicity by PS in all 13 spontaneous cases as opposed to initial judgment that suggested a toxic potential of PS. Major shortcomings emerged in the pharmacovigilance section that require urgent improvements.
lifications in pharmacovigilance are desired, 2 and adherence to guidelines for submitting adverse reaction reports is recommended 3 to meet the requirements for complete case data, which currently often are of low quality. [4] [5] [6] Adverse reactions associated with the use of conventional drugs and herbs are not uncommon, and most of these may easily be recognized, but this does not necessarily apply to cases of rare drug induced liver injury (DILI) or herb induced liver injury (HILI). For cases of liver injury, a thorough causality assessment is more important 7, 8 than generating signals of safety concerns simply by counting spontaneous reports or published case reports. 9 At present, pharmacovigilance and clinical considerations contribute to the discussion whether the use of PS (Pelargonium sidoides DC) may be hepatotoxic. [10] [11] [12] PS is a plant of southern African origin, and water/ethanol extracts from its roots are mainly used in European countries. 10 In Germany, PS extracts are marketed since at least 1976 and are registered as a herbal medicinal product with the indication for symptomatic treatment of acute bronchitis; indications in other countries may be broader, but focus on respiratory tract infections including common cold. 10, 11 In 2011, EMA (European Medicines Agency) described a favorable benefit/risk ratio and a lack of unwanted hepatic effects in causal relationship to PS use in European countries. 10 Surprisingly, in the same year 19 spontaneous reports on assumed PS hepatotoxicity collected since 2004 were published in Germany, 11 but causality for PS could not be substantiated upon further assessment. 12 In the present study we assessed causality for PS in additional spontaneous cases of assumed PS hepatotoxicity in purported connection with PS use partially going back to 2004. These cases were presented in 2011 by European regulatory agencies, the WHO, and the manufacturer. None of these cases now presented has been thoroughly evaluated for causality before.
MATERIAL AND METHODS

Patients
Overall 13 patients were evaluated as study group that included cases of spontaneous reports with liver disease in primarily assumed temporal and causal association with Pelargonium sidoides (PS) treatment. The patients originated from Germany (n = 9), Switzerland (n = 2), Italy (n = 1), and Singapore (n = 1). Case data were supplied by the German regulatory agency (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM, Bonn, Germany) for 6 cases without final assessment and/or presentation of causality levels, but with the understanding that the global introspection WHO scale has been used, a method which is not liver-specific and not validated for hepatotoxicity and thereby in no way an acceptable method for causality assessment of regulatory assumed HILI cases by PS; additional data of these 6 cases were presented by the manufacturer. Data of the remaining 7 cases were kindly provided upon request by the manufacturer (Dr. Schwabe, Karlsruhe, Germany) of one of the PS drugs; among these was one case initially presented to and now provided by the WHO database to the manufacturer upon its actual request. The case of a 46-year-old female patient with comedicated polytherapy and LTX was not further assessed due to various confounding variables such as comedication, poor data quality, and lack of an established temporal association, because short term PS treatment was initiated to treat flu like symptoms erroneously not considered as prodromi of the emerging liver disease at that time.
PS is available in the form of film-coated tablets and oral liquid. 10 For adult patients, the recommended dose in Germany is 3 x 30 drops daily which corresponds to 3 x 1 tablet 20 mg each daily. According to the patient leaflet, treatment should not exceed 3 weeks.
Methods
All data of the patients were supplied in anonymous form. The information commonly consisted of a condensed form presented to or generated by BfArM. A condensed form as well as narrative information was also provided by the drug manufacturer. In a few cases only, the data also included a medical report of the treating physician, a discharge report, and an adverse drug reaction report.
The data of all 13 cases were submitted to a causality algorithm that consisted of 4 steps: assessment of key items related to a temporal association (step 1), criteria of PS hepatotoxicity and definition of the pattern of liver injury (step 2), application of an appropriate causality assessment method (step 3), and exclusion of alternative diagnoses (step 4). [13] [14] [15] Evaluations also included synthetic drugs and other herbs.
In the first step, clear information is required for timetables with respect to start and end of PS use as 11 (4) : 500-512 502 well as to the appearance of symptoms and/or increased liver values. For the second step, values of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) are essential as clear criteria for liver injury and for the differentiation between the hepatocellular, cholestatic or mixed hepatocellularcholestatic pattern. 13, 15 The third step of the diagnostic algorithm requires the application of the liver specific, for hepatotoxicity validated, structured, quantitative and updated scale of CIOMS (Council for International Organizations of Medical Sciences); [15] [16] [17] for reasons of comparison the original CIOMS scale was also used. 13 In the fourth step, all case data were analyzed regarding various other differential diagnoses not yet evaluated with the updated CIOMS scale. 15 
RESULTS
Basic data of the study group
In the study group of 13 patients, the ratio of males:females was 7:6, and in 12 of these the ages were known with a range from 31 to 81 years and an average of 56.7 years ( Table 1) . The indication for PS treatment was described for 11 of the 13 patients and included unspecific infection, flu like symptoms, sinusitis, sinubronchitis, nasopharyngitis, pharyngitis, and infections of the upper respiratory tract including bronchitis. The brand name and the manufacturer of the used herbal PS drug were available in all 13 cases (Tables 1 and 2 ). PS was used as a clearly identifiable monopreparation in all cases; no patient took a herbal mixture preparation (Table 2 ). In 9 patients comedication was reported that consisted of up to 9 chemical drugs, suggesting multimorbidities. Apart from PS, in none of the cases was there any additional use of a herbal drug or a dietary supplement except for one who used a gel with arnica contained in a herbal drug (Tables 1 and 2 ).
The daily dose of the used PS drug was known in only 9 out of 13 cases: of these 4 patients adhered to the recommended daily dose of 3 x 30 drops (n = 3) or 3 x1 tablet with 20 mg extract (n = 1); with 3 x 50 drops daily PS overdose was reported for 1 patient; underdosed PS treatment was described for the remaining 4 patients who daily used 1 x 20 drops (n = 1), 1 x 30 drops (n = 1), or 3 x 20 drops (n = 2) (Tables 1 and 2 ). In four cases corresponding to almost one third of the patients the daily dose of PS remained unclear.
Incomplete data were also obtained for other items such as beginning and end of PS use and appearance of symptoms, total time on PS, time to onset to assess the latency period, and verification of a temporal association (Tables 1 and 2 ). The exact dates of PS start and end were presented for 7 and 9 patients, respectively. As a consequence, time on PS signifying overall treatment duration was known only in 7 cases (Table 2) ; with 5 patients who used PS between 2 and 11 days with an average of 5.8 days and with 2 other patients who were treated for 30 and 180 days. This reflects overlong treatment because drug information limits PS use to a maximum of 21 days (Table 1) . Whereas the exact date of symptoms or increased liver values were described in 10 of 13 patients, the time to onset considered as latency period was known only in 6 cases with an established temporal association in 5 cases (Table 2 ).
Clinical and laboratory data
Symptoms were reported by the physicians only rarely, as were considerations of differential diagnoses that were usually required to assess the causes of increased liver values (Table 1) . Outcome was favourable in 12 patients and fatal in 1 patient with preexisting liver cirrhosis due to a chronic active hepatitis on the basis of an ANA positive AIH that required steroid treatment and finally led to a terminal aspergillus sepsis.
Among the 13 study patients, values of ALT, AST AST (aspartate aminotransferase), and ALP were available in 8, 6, and 5 cases, respectively (Tables 1  and 2 ). ALT was on average 1,041 U/L with a range of 101 to around 2,500 U/L; with AST, the average was 1,288 U/L and a range from 49 to around 4,000 U/L; and ALP showed an average value of 140 U/L with a range of 63 to 178 U/L (Table 1) . ALT values following PS cessation were reported in 6 cases and found decreased, but in none of the overall 13 patients ALT normalization has been reported (Tables  1 and 2 ). Therefore, in none of these cases the diagnosis of an acute and resolving liver disease is warranted. In some of the remaining cases, any form of chronic liver disease may be present, including AIH that has only rarely been excluded in the overall 13 patients (Table 1) .
Overall hepatitis serology and imaging data was poorly documented in most of the 13 cases (Tables  1 and 2 ). In only 5 or less cases was there any information on biliary tract imaging, hepatitis A, hepatitis B, or hepatitis C, and in only 2 cases hepatitis E was assessed. Data of infections by cytomegalovirus, Epstein Barr virus, or herpes • Final diagnoses: Hepatitis associated with virus or bacterial infection; NSAID hepatotoxicity; unassessed hepatobiliary disease.
• Causality: Unlikely causality with respect to PS according to CIOMS criteria.
• There was lack of laboratory data to assess the cause of the increased liver values, and there were no imaging results of the hepatobiliary system although recommended.
• Final diagnosis: Liver injury by antibiotic drug; not further classified liver disease.
• Comment: Poorly documented case. Prolonged PS treatment. The report of the hepatobiliary sonography describes that there is no passage of a biliary stone, but there is lack of details regarding gall bladder, bile ducts within and outside the liver, and pancreas. Comedication with paracetamol (1,000 mg/d), but no details presented. Known penicillin allergy and multiple other allergies, arterial hypertension without specified treatment, and type II diabetes mellitus without specified treatment. The hospital diagnosis is drug induced jaundice or calculus passage.
• Final diagnoses: Acute pancreatitis and cholangitis, possibly related to transient choledocholithiasis; paracetamol hepatotoxicity.
• Causality: Possible causality with respect to PS only on formal grounds according to CIOMS criteria, but this particular judgement is actually a false positive signal in face of the established alternative and final diagnosis.
• • Final diagnoses: Unassessed acute virus hepatitis, acute cholecystitis, and aspirin induced liver injury.
• Comment: Unusual and poorly documented case. The initial assessments of the aminotransferases show much higher values for AST compared to ALT, which results in a De-Ritis quotient of > 6. This may be found in alcoholic liver disease, cardiac and muscle diseases, but due to lack of additional laboratory values a final diagnosis is not feasible. Considering the flu like symptoms as prodromi, the present illness may well be attributed to a virus hepatitis. There was contact with a patient with hepatitis B and C, and this diagnosis might have been missed through insufficient parameters and due to missing surveillance with respective parameters in the further course. Overall, hepatitis A-C and E as well as the other forms of hepatitis should have been clearly ruled out. • Final diagnoses: ANA positive AIH with chronic active hepatitis and preexisting, liver cirrhosis; liver injury by comedication (Olmetec®).
• Causality: Excluded causality with respect to PS according to CIOMS criteria.
• Comment: Dark urine as first symptom of liver disease was noticed few days after PS start, incompatible with PS hepatotoxicity. PS overdose: 3 x 50 drops used instead as recommended 3 x 30 drops per day. AIH, responding to prednisone therapy. • Final diagnosis: Infliximab hepatitis.
• Comment: Hepatitis due to Infliximab that started with acute nasopharyngitis as prodromi. As a slowly metabolized drug with elimination of up to 6 months, Infliximab runs the risk of cumulation. Alternative hepatitis E with rapid IgM disappearance not excluded with certainty. Lack of temporal association with respect to PS. In a note later on the practitioner reported actually an increase of the aminotransferases at two different occasions: at first, there was comedication with a potentially hepatotoxic antibiotic drug of not declared product identity or manufacturer, and at second, there was no comedication, a threefold increase of aminotransferases (not specified in detail) and a reduction of the values in the further course after drug cessation without any details with respect to the time frame. Bronchial asthma and multiple allergies were reported as underlying diseases. The practitioner assumes a possible causality for PS.
• Final diagnoses: None, due to poor documentation.
• Comment: Poorly documented case. Whether there is a temporal association at all, is doubtful or at least not clearly documented. There are no data that exclude alternative causes of the observed liver disease, a possible reexposure test is invalid due to insufficient data, and a chronic liver disease has not been excluded, since normal values of aminotransferases before and after PS use have not been presented. Prolonged treatment duration. • Final diagnosis: Hepatic involvement following pneumothorax contusion.
• Comment: Due to lack of a temporal association, there is no causality for PS. On the day PS treatment was initiated. ALT was already increased. Consequently, any medication initiated at August 11, 2009 has to be excluded as cause, not only PS but also the potentially hepatotoxic etrocoxib and ranitidine. Any other comedication used for various comorbidities has to be considered, since some are potentially hepatotoxic. But these comedications have been used for a long period, possibly without major hepatic adverse effects. Increased liver values are best explained with the consequences of traumatic pneumothorax contusion with liver involvement. Furosemid, and Allopurinol, and most of these drugs are considered potentially hepatotoxic. Comorbidity included Italy congenital heart disease, oligophrenia, and epilepsy. There was no exclusion of any form of hepatitis, genetic and autoimmune liver diseases.
• Final diagnoses: Preexisting liver disease; hepatotoxicity by comedicated drug(s), cardiac hepatopathy.
• Comment: Poorly documented, basically not assessable case. Lack of exclusion of hepatitis A-C and E, CMV, EBV, HSV, VZV, and autoimmune liver diseases. Biliary diseases not excluded by hepatobiliary sonography. Short-term use of PS for 4 days with one third of the recommended daily dose. simplex virus was provided for 3 or less patients and was lacking in the remaining cases. In none of the cases infections by varicella zoster virus have been ruled out. Because common forms of hepatitis have not been ruled out in 8 or more cases, data quality is considered low.
Disease classification and pattern
Criteria for hepatotoxicity as a disease requiring ALT and/or ALP values of at least 2 x N were fulfilled in 8 out of 13 patients but not in the remaining 5 patients (Table 2 ). In these 5 cases uncertainty prevails whether hepatotoxicity as a well defined liver disease really exists.
Both ALT and ALP as required criteria for assessing the hepatotoxicity pattern were provided in 5 cases (Table 2 ). Since these criteria were only rarely available (Tables 1 and 2 ), clear laboratory differentiation to assess the pattern of liver injury was not feasible. Criteria for the pattern of liver injury in these 5 patients showed a hepatocellular pattern of injury; it was assumed, on grounds of practicability, that this form prevailed in all other cases to facilitate causality assessment.
Causality assessment
With the updated CIOMS scale applicable to the hepatocellular type of liver injury, none of the 13 cases with liver disease had a highly probable or probable causality level for PS (Table 3 ). In 6 cases causality was excluded and in another 6 cases unlikely. Causality for PS was possible on the basis of the CIOMS items in 1 patient (case 3), but this judgement likely represents a false positive signal in 
Final diagnoses
Despite the low data quality found in most cases and on the basis of clinical judgements, there were numerous diagnoses causally unrelated to the use of PS in the 13 patients analyzed in this study (Table  1) . Final alternative diagnoses include a wide variety of diseases including hepatitis associated with virus or bacterial infections, DILI, acute pancreatitis and cholangitis, acute cholecystitis, ANA positive autoimmune hepatitis (AIH) with chronic active hepatitis and preexisting liver cirrhosis, other preexisting liver diseases, and hepatic involvement following lung contusion.
DISCUSSION
Adverse herb reactions are major challenges, both in the clinical and regulatory field, [18] [19] [20] [21] [22] particularly when suspected cases of HILI are to be considered. [23] [24] [25] [26] The present analysis evaluated spontaneous cases of primarily assumed PS hepatotoxicity; in none of the 13 cases evidence was found for an overt hepatotoxic potential causally related with PS use (Tables 1 and 3 ). These results are in line with conclusions from previous reports on PS in 15 cases 12 and in another case presented by EMA. 10 In the past, lack of hepatotoxicity has also been shown for other herbs such as black cohosh (BC), 27, 28 whereas rare cases of liver injury were reported in connection with the use of kava 29, 30 or Greater Celandine (GC). 31, 32 In all primarily suspected cases associated with the use of PS, BC, kava, and GC, identical methods have been employed, namely the original and updated CIOMS scale. This confirms that different results obtained for all 4 herbs reflect differences in the individual herbal product to potentially cause liver injury rather than differences in the evaluating methods. For other herbs such as Ayurvedic herbs, Chaparral, Chinese herbal mixture, Chinese Jin Bu Huan, Chinese Ma-huang, Chinese Syo-saikoto, Herbalife®, Mistletoe, and Senna, hepatotoxicity has previously been established in most cases by positive reexposure tests. 28 Thus, hepatotoxicity may be ascribed to various herbal medications but not to PS.
Less than 4 causes of group I ruled out -2 -2 -2 -2 Non drug cause highly probable -3 -3 -3 -3 -3 -3 -3 -3 -3 -3 -3
Previous information on hepatotoxicity of the drug
Reaction labelled in the product characteristics +2 +2 +2 +2 +2 +2 +2 +2 +2 +2 +2 +2 +2 +2 Reaction published but unlabelled +1 Reaction unknown 0
Response to readministration
Doubling of ALT with the drug alone +3 Doubling of ALT with the drugs already given at the time of first reaction +1 Increase of ALT but less than N in the same conditions as -2 for the first administration Other situations 0
Total points for patient +02 +01 +04 +02 0 +01 -03 0 +02 0 +02 -01 0
In all 13 patients with primarily suspected Pelargonium sidoides (PS) hepatotoxicity, causality assessment for PS was performed with the updated scale of CIOMS (Council for International Organizations of Medical Sciences), considering the items for the hepatocellular type of liver injury as defined previously. 7, 13, 15 In the section 6 of concomitant drug(s), the following products were considered: synthetic drugs, dietary supplements including herbal ones, and polyherbal products. In the section 7 (search for non drug causes), the symbol of -denotes that the obtained result was negative and that of + was positive, whereas lack of a symbol indicates that assessment was not performed. All data were also submitted to the original CIOMS scale 13 
